BLK
BlackRock, Inc.
BLK's fundamentals are mixed, but it looks expensive: trading at 28x earnings, above its usual 22x.
NMR
Nomura Holdings, Inc.
There isn't enough reported data to score NMR yet.
BLK Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BLK's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BLK.
NMR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| N/A | |
| N/A |
NMR's profitability is currently healthy. There isn't enough data to rate its revenue. Free cash flow and net leverage aren't meaningful measures for financial services companies like NMR.
BLK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 19x | $848 | -30% |
| Fair | 22x | $973 | -20% |
| Expensive | 26x | $1,149 | -5.5% |
| Current | 28x | $1,217 | — |
Historical ranges are pointers, not guarantees.
BLK has the edge over NMR in the historical PE scenario, which offers more potential upside but is not a forecast.
NMR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.9x | $5.90 | -38% |
| Fair | 12x | $8.70 | -9% |
| Current | 13x | $9.56 | — |
| Expensive | 18x | $13.82 | +45% |
Historical ranges are pointers, not guarantees.
NMR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
BLK Forward outlook
There aren't enough analyst estimates for BLK to show an outlook.
NMR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| High |
Analysts expect NMR's revenue to grow, but its profitability to weaken.
BLK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $43.87 | +11% |
| Q2 2026 | $41.73 | -0.4% |
| Q1 2026 | $39.73 | -4.7% |
| Q4 2025 | $35.31 | -17% |
| Q3 2025 | $39.42 | -2.7% |
| Q2 2025 | $41.89 | +4% |
| Q1 2025 | $41.69 | +5.9% |
| Q4 2024 | $42.53 | +16% |
BLK earned $43.87 per share over the past year, up 11% from the year before.
NMR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2026 | $0.75 | +7.1% |
| Q3 2025 | $0.76 | +36% |
| Q1 2025 | $0.70 | +112% |
| Q3 2024 | $0.56 | +107% |
| Q1 2024 | $0.33 | +74% |
| Q3 2023 | $0.27 | +23% |
| Q1 2023 | $0.19 | -32% |
| Q3 2022 | $0.22 | +$0.23 |
NMR has the edge over BLK in the latest year-over-year earnings comparison.
BLK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.8B | +19% |
| Q2 2026 | $7.1B | +31% |
| Q1 2026 | $6.7B | +27% |
| Q4 2025 | $7B | +23% |
| Q3 2025 | $6.5B | +25% |
| Q2 2025 | $5.4B | +13% |
| Q1 2025 | $5.3B | +12% |
| Q4 2024 | $5.7B | +23% |
BLK's revenue has grown year over year for 13 quarters in a row: $7.8B last quarter, up 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | 0 points |
| Q2 2026 | 35% | +2.8 points |
| Q1 2026 | 42% | +9.8 points |
| Q4 2025 | 24% | -13 points |
| Q3 2025 | 30% | -8.6 points |
| Q2 2025 | 32% | -5.5 points |
| Q1 2025 | 32% | -3.6 points |
| Q4 2024 | 37% | +2.3 points |
BLK's operating margin was 30% last quarter, about level with the same quarter a year ago, near the bottom of its range since 2019.
NMR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $7.1B | +18% |
| Q3 2025 | $6.5B | +11% |
| Q1 2025 | $6B | +13% |
| Q3 2024 | $5.9B | +31% |
| Q1 2024 | $5.3B | +18% |
| Q3 2023 | $4.5B | +16% |
| Q1 2023 | $4.5B | +3.9% |
| Q3 2022 | $3.9B | -8.2% |
NMR has the edge over BLK in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | 21% | -0.3 points |
| Q3 2025 | 28% | +14 points |
| Q1 2025 | 25% | +6.3 points |
| Q3 2024 | 25% | +18 points |
| Q1 2024 | 21% | +2.6 points |
| Q3 2023 | 15% | +0.9 points |
| Q1 2023 | 18% | +26 points |
| Q3 2022 | 7.8% | -24 points |
NMR's operating margin was 21% last quarter, about level with the same quarter a year ago.
BLK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.6B | +95% |
| Q2 2026 | $1.1B | -12% |
| Q1 2026 | -$1.1B | +$120M |
| Q4 2025 | $2.1B | -15% |
| Q2 2025 | $1.3B | -6.1% |
| Q1 2025 | -$1.2B | -$734M |
| Q4 2024 | $2.5B | +35% |
| Q2 2024 | $1.4B | +47% |
BLK's free cash flow was $4.8B over the past year, up 22% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BLK.
NMR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$12.7B | -$10.1B |
| Q3 2025 | $5.2B | +$8B |
| Q1 2025 | -$2.6B | -$1.6B |
| Q3 2024 | -$2.8B | -420% |
| Q1 2024 | -$968.3M | -$27.3M |
| Q3 2023 | $885.9M | +$5.4B |
| Q1 2023 | -$941M | +$6.6B |
| Q3 2022 | -$4.5B | -$2.8B |
NMR's free cash flow was −$12.9B over the past year, against −$5.5B the year before. Free cash flow isn't a meaningful measure for financial services companies like NMR.
BLK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -148K shares |
| 1 year | -0.4% | -677K shares |
| 3 years | +9.3% | +14M shares |
| 5 years | +6.2% | +9.6M shares |
| Available history | +4.4% | +7M shares |
BLK has 165M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | $396M |
| Q1 2025 | $657M |
| Q4 2024 | $386M |
| Q2 2024 | $519M |
| Q1 2024 | $634M |
| Q4 2023 | $384M |
| Q3 2023 | $396M |
| Q2 2023 | $383M |
NMR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -9.6% | -325M shares |
| 1 year | -14% | -498M shares |
| 3 years | -20% | -781M shares |
NMR has the edge over BLK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2026 | $260.1M |
| Q3 2025 | $376.1M |
| Q1 2025 | $50,144 |
| Q3 2024 | $369.8M |
| Q1 2024 | $257.1M |
| Q3 2023 | $125.4M |
| Q1 2023 | $9.5M |
| Q3 2022 | $145.5M |
BLK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.0x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2024 | 0.2x | Very low |
| Q1 2024 | 0.3x | Very low |
| Q4 2023 | 0.1x | Very low |
BLK has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like BLK.
NMR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 21.7x | High |
| Q3 2025 | 16.5x | High |
| Q1 2025 | 18.8x | High |
| Q3 2024 | 19.0x | High |
| Q1 2024 | 26.8x | High |
| Q3 2023 | 28.2x | High |
| Q1 2023 | 31.5x | High |
| Q3 2022 | 32.4x | High |
NMR's net debt is more than 20 years of its operating earnings (EBITDA), down from more than 20 years a year ago. Net leverage isn't a meaningful measure for financial services companies like NMR.
BLK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.5 | Neutral |
| Stochastic | 79.0 | Neutral |
BLK's weekly RSI is 64 (neutral) and its Stochastic is 79 (neutral).
NMR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.8 | Neutral |
| Stochastic | 26.2 | Neutral |
NMR's weekly RSI is 53 (neutral) and its Stochastic is 26 (neutral).
BLK PE vs Financial Services Sector
| Metric | BLK | Sector median | Relative |
|---|---|---|---|
| PE | 28x | 13x | 113% above |
| PE % | 97 | 63 | 34 pts above |
BLK is trading at 28x earnings, a 113% premium to the Financial Services sector's median of 13x.
NMR PE vs Financial Services Sector
| Metric | NMR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 13x | 1.5% below |
| PE % | 59 | 63 | 4 pts below |
NMR has the edge over BLK on valuation relative to its sector.
BLK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,128.0 | 7.9% above |
| 20 week MA | $1,108.9 | 9.7% above |
| 50 week MA | $1,071.6 | 14% above |
| 100 week MA | $1,051.1 | 16% above |
| 200 week MA | $914.1 | 33% above |
BLK has the edge over NMR on trend strength, trading above more of its moving averages.
NMR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.49 | 0.7% above |
| 20 week MA | $9.75 | 1.9% below |
| 50 week MA | $8.94 | 6.9% above |
| 100 week MA | $7.73 | 24% above |
| 200 week MA | $6.28 | 52% above |
NMR's trend is mixed: it's above four of its five weekly moving averages, and 52% above its 200-week average.
BLK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $503.0 | $707.2 | +41% |
| 2021 | $707.2 | $913.9 | +29% |
| 2022 | $913.9 | $703.9 | -23% |
| 2023 | $703.9 | $811.8 | +15% |
| 2024 | $811.8 | $1,044.2 | +29% |
| 2025 | $1,044.2 | $1,088.1 | +4.2% |
| 2026 YTD | $1,088.1 | $1,216.6 | +12% |
BLK has finished higher in five of the last six years. It's up 12% so far in 2026.
NMR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.12 | $5.22 | +2% |
| 2021 | $5.22 | $4.43 | -15% |
| 2022 | $4.43 | $3.68 | -17% |
| 2023 | $3.68 | $4.51 | +23% |
| 2024 | $4.51 | $5.86 | +30% |
| 2025 | $5.86 | $8.41 | +44% |
| 2026 YTD | $8.41 | $9.56 | +14% |
NMR has the edge over BLK on returns for 2026, with the stronger performance.